Introduction
The genus Burkholderia comprises more than 40 species, which inhabit diverse ecological niches such as soil and water, plant surface and rhizosphere, and animal and human respiratory tract [10, 11, 54] . Some of the best known Burkholderia species are the B. cepacia complex 1 3 natural product chemistry approach, this mini-review only covers those discovered by genome-guided approachesthese refer to the use of bacterial genome sequence as an entry point for in silico structural prediction, wet lab experimental design and execution-to be in compliance with the theme of this special issue of JIMB. In addition, this mini-review does not elaborate on the technical details of genome mining and genome-guided discovery approaches because such topics are covered by other articles published in this special issue of JIMB or elsewhere [8, 12, 55, 63] .
Betulinan/terferol analogues
Betulinans A-C ( Fig. 1 ) are benzoquinone compounds isolated from the fruiting bodies of Lenzites betulina and the culture of a fungus belonging to the Order of Chaetothyriales [16, 29] . Terferol ( Fig. 1) is a terphenyl compound discovered from the culture of Streptomyces sp. in a screening for eukaryotic phosphodiesterase (PDE) inhibitors [36, 37] .
The Brady group identified a cryptic gene cluster BTH-II0204-207 in the B. pseudomallei K96243 genome and a highly similar gene cluster in the B. thailandensis E264 genome. They PCR-amplified the gene clusters from respective genomic DNA, cloned under the control of an IPTG-inducible P tac promoter, and introduced the constructs into Pseudomonas aeruginosa by conjugation for heterologous expression. Multiple new peaks appeared in the HPLC trace of ethyl acetate extract of the transformed P. aeruginosa culture induced by IPTG, which led to the discovery of four betulinan/terferol analogues, named BTH-II0204-207:A-D (1-4) ( Fig. 1 ) [3] . These compounds differ from betulinans or terferol by either the position or number of methyl substituents found on each metabolite. The BTH-II0204-207 gene cluster contains four genes that encode a single module nonribosomal peptide synthetase (NRPS), a dehydratase, an isomerase, and a methyltransferase. It was predicted that the NRPS module condenses two phenylalanine units to initiate the biosynthesis of BTH-II0204-207:A through a mechanism that is similar to the biosynthesis of the fungal metabolite terrequinone [3, 6] . Although the methyltransferase is assumed to account for the varied methylation patterns of the betulinan/terferol analogues, the exact roles of the predicted dehydratase and isomerase enzymes remain unknown; it is also not clear how the amino groups are removed.
Bioactivity assay indicated that BTH-II0204-207:A is a potent PDE4 inhibitor [3] . Noteworthy, the first selective PDE4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD), roflumilast (DALIRESP ® ), was approved by the US Food and Drug Administration (FDA) in 2011 [51] . Betulinans, terferol, and their congeners have thus been regarded as promising drug candidates targeting PDE4-related disease such as COPD, some types of brain tumors, and other inflammatory diseases [20, 27, 34, 43] .
During the same course of study, the Brady group heterologously expressed another small cryptic gene cluster BPSS2111-2113 from B. pseudomallei K96243 and isolated three non-betulinan compounds named BPSS2111-2113:A-C (5-7) (Fig. 1) . These compounds share a 7-hydroxy-2H-benzo[b] [1, 4] thiazin-3(4H)-one core structure but BPSS2111-2113:B-C have two to three methyl mercapto substitutions, respectively. The biosynthetic origin or bioactivities of those compounds was not investigated [3] .
Capistruin
Lasso peptides are ribosomally synthesized bioactive peptides consisting of 16 to 21 amino acids featuring a C-terminal tail that threads through an N-terminal macrolactam ring to form a tightly knotted structure [21, 32] . This structural conformation endows the peptides resistance to proteolysis and varying bioactivities including inhibition of HIV replication, inhibition of bacterial RNA polymerase, and induction of mitochondrial permeability and the subsequent loss of cytochrome c [14, 42, 57] . Lasso peptides are classified depending on the presence (class I) or absence (class II) of four conserved cysteine residues, which are involved in the formation of two intramolecular disulfide bonds [47] . The best studied lasso peptide is microcin J25 (MccJ25) (Fig. 2) The Marahiel group identified a gene cluster homologous to the E. coli mcjABCD operon in the genome of B. thailandensis E264 and predicted this strain to produce a class II lasso peptide. They went on to optimize the fermentation conditions for elevated gene expression and successfully isolated the predicted peptide, named capistruin (8) (Fig. 2 ) [25] . Mass spectrometric and NMR structural studies confirmed the lasso structure of capistruin. Heterologous expression of capABCD in E. coli was sufficient to produce the matured capistruin peptide. Capistruin consists of 19 amino acids and is maturated from a 47-amino acid precursor CapA. CapB and CapC are protease and synthetase/cyclase, respectively, for processing CapA, and CapD is an export and immunity protein. It was proposed that during capistruin maturation, CapB cleaves off the first 28-amino acid leader peptide on CapA to free the N-terminal glycine (G1), and CapC activates the side-chain carboxyl group of aspartic acid (D9) to promote the condensation (C) reaction to form a 9-residue macrolactam ring. The tight threading of the 10-residue C-terminal tail through the macrolactam ring in mature capistruin suggests the CapA precursor has to be folded correctly beforehand, so that the ring is enclosed around the C-terminal tail [26] .
Capistruin was found to possess moderate antimicrobial activities against representative Burkholderia, E. coli and Pseudomonas strains, with MIC values in the range of 12-50 μM [25] .
Malleilactone/burkholderic acid
When surveying the genomes of Burkholderia sp., the Brady group and the Hertweck group independently identified a cryptic gene cluster commonly present in the genomes of B. mallei ATCC 23344, B. pseudomallei K96243 and B. thailandensis E264. This gene cluster encodes a noncanonical hybrid polyketide synthase (PKS)-NRPS pathway that contains unusual domains and module organization, from which no putative compound structure could be predicted. After having performed promoter exchanges in B. thailandensis E264 to activate this enigmatic pathway either by rhamnose induction (the Brady group) or by a constitutively expressed promoter design (the Hertweck group), both groups observed a significantly elevated production of an unknown compound during HPLC profiling of culture extracts of the engineered strains, which eventually led them to discover the elusive yellow pigment compound, named malleilactone (9) by the Brady group [4] or burkholderic acid (10) by the Hertweck group [17] (Fig. 3) . During the course of compound purification, the Hertweck group noticed that the burkholderic acid was highly unstable until a methylation reaction was performed to convert the labile compound into a stable methylated derivative. Isotope labeling and NMR structural studies finally solved the structure of this mysterious compound. Malleilactone/burkholderic acid appeared to exist naturally as tautomers.
In preliminary assays the Brady group found malleilactone to possess weak to moderate activities against some Gram-positive bacteria and human cell lines [4] . Independently, the Hertweck group found burkholderic acid and its methylated derivative to have no antimicrobial activity and only weak to moderate cytotoxicity [17] . Malleilactone/burkholderic acid and its tautomeric butenolide bear significant structural similarity with bacterial quorum sensing molecules such as A-factor and N-acyl homoserine lactone (AHL) (Fig. 3) ; they are likely involved in microbial communication.
Because of the unusual domains and module organization of the deduced hybrid PKS-NRPS pathway for malleilactone/burkholderic acid biosynthesis, the elucidation of the compound structure retrospectively assisted the Hertweck group to propose a biosynthetic model. In this model, one longer aliphatic chain is built from a shortchain fatty acid that is activated by a CoA ligase BurJ. This C8 intermediate is loaded onto an acyl carrier protein (ACP) on BurF and elongated by two PKS cycles to G1   G4   G17   T2  P3   F5  Q6   D9   A10   R11  V12   I13   S14   R15   F16   F18  N19   P8  G1   G4   G2   A3  H5  V6   Y9   F10   V11  G12  I13  G14   T15  P16   G21   E8   S18   F19   I17   Y20 Capistruin ( (9) and its tautomer burkholderic acid (10) form a C12 intermediate covalently linked to the last ACP on BurF. Meanwhile, a shorter aliphatic chain is initiated by a propionyl unit derived from methionine, followed by one cycle of PKS extension of a hydroxymalonyl moiety to form a C5 intermediate covalently linked to an ACP on BurA. Although it is uncertain about how the transamination, decarboxylation and desulfurization of the methionine might occur, it is likely that a C domain on BurF is responsible for bringing together the two enzyme-bound aliphatic chains by forming an ester bond. Finally, a reductase (Red) domain at the C-terminal of BurF cleaves the ACP-bound intermediate, which further undergoes a spontaneous cyclocondensation to afford malleilactone/burkholderic acid [17] .
Thailandamides and thailandamide lactone
When surveying the bacterial genomes for trans-acyltransferase (AT) PKSs, the Piel group, in collaboration with the Hertweck group, identified a giant cryptic gene cluster in the genome of B. thailandensis E264, which encodes a 17-module hybrid trans-AT PKS-NRPS pathway [41] . The authors predicted two slightly different versions of a complicated long chain polyene product using two distinctive prediction methods, which led to the discovery of thailandamide A (11), its congener thailandemide B (12), and thailandemide lactone (13) (Fig. 4) [22, 23, 41] . Those compounds are elusive because they are produced in minute amounts only in the early growth phase, and they undergo rapid heat-and light-induced decomposition. The Hertweck group had overcome those technical difficulties by manipulating the bacterial quorum sensing regulation to upregulate the tha gene cluster expression, by optimizing the cultivation conditions, by scaling up the fermentation volume, and by performing all purification steps in total darkness within a few hours. Eventually, they obtained enough compounds for structure elucidation and bioactivity assays. pathway regulator, and genes for discrete PKS domain proteins, tailoring enzymes and other functionally unknown proteins [22] . A model for the biosynthesis of thailandamides was proposed, in which an NRPS module on ThaH is predicted to directly activate a D-Ala substrate [23] . Thailandamide lactone showed moderate antiproliferative activities against human tumor cell lines [22] .
Thailandepsins/burkholdacs
The genome of B. thailandensis E264 contains another cryptic gene cluster (BTH_I2369-2357) that resembles the FK228 biosynthetic gene cluster in Chromobacterium violaceum No. 968 [9, 46, 60] . Two groups independently worked on this gene cluster around the same time frame. The Brady group employed an overexpression of transcriptional factor approach to elevate the production of natural products, which led to their discovery of burkholdac A (16) and burkholdac B (14) (Fig. 5 ) [2] . Our group used a gene knockout approach to disrupt the production of natural products as shown by the disappearance of several HPLC peaks, which led to the discovery of thailandepsin A (14) and thailandepsin B (15) (Fig. 5 ) [59] . Burkholdec B and thailandepsin A refer to the same compound. Subsequently our group further discovered thailandepsins C-F (16-19) (Fig. 5 ) by supplementing amino acid precursors to the fermentation medium of B. thailandensis E264 [58] . Burkholdacs/thailandepsins all have a bicyclic depsipeptide framework but differ from each other by having different amino acid side chains. They are natural structural analogues of FK228 [52, 53] , an FDA approved anticancer drug for the treatment of refractory cutaneous T-cell lymphoma [56] and peripheral T-cell lymphoma [61] . FK228 is a potent inhibitor of class I human histone deacetylases (HDACs); differential inhibition of HDACs in cancer cells leads to a cascade of chromatin remodeling, tumor suppressor gene reactivation, apoptosis, and cell death [18, 53] . The tdp gene cluster responsible for the biosynthesis of thailandepsins contains 13 ORFs, which include tdpABC-1 DE 1 C 2 E 2 coding for a seven-module hybrid NRPS-PKS pathway, tdpH for a disulfide oxidase, thaR for an AraRtype pathway regulator, and genes for tailoring enzymes, self-resistance and other functionally unknown proteins. A model for the biosynthesis of thailandepsins was proposed, in which a yet-to-be-identified discrete protein provides the necessary trans-AT activity for biosynthesis [59] .
Our group and collaborators conducted extensive enzyme assays and showed that thailandepsins are potent HDAC inhibitors, particularly toward HDAC1-3 which belong to class I human HDACs, with half-maximal enzyme inhibition (IC 50 ) values in the single to sub nM range [58, 59] . Cellbased antiproliferative assays indicated that thailandepsins A and B possess a broad spectrum of growth inhibition activities, and has reached half-maximal growth inhibition (GI 50 ) for over 90% of the tested NCI60 cell lines even at the lowest concentration (10 −8 M) used in the screening. Most interestingly, thailandepsin A demonstrated differential activities toward certain types of cell lines at total growth inhibition (TGI) and half-maximal lethal inhibition (LC 50 ) levels, particularly for those derived from colon, melanoma and renal cancers. The efficacy and long-term toxicity of thailandepsin A and thailandepsin B are being investigated in animal models.
Thailanstatins
FR901464 was the first identified natural product which inhibits eukaryotic pre-mRNA splicing [38] [39] [40] . The genetic basis for FR901464 biosynthesis in Pseudomonas sp. No. 2663 has been decoded [62] . FR901464 is biosynthesized by a hybrid PKS-NRPS pathway that features a trans-AT PKS system complemented by three discrete ATs. Using the deduced FR9 proteins as templates to search the GenBank, our group identified a cryptic gene cluster in the genome of B. thailandensis MSMB43 that resembles that of FR901464. We obtained the bacterial strain from the US Centers for Diseases Control (CDC), cultivated it in nine different media and used RT-PCR to detect a cultivation condition of Medium 9 in which a regulatory gene of the cryptic gene cluster (tstA) is adequately expressed. (21), and thailanstatin C (22) and C (22) , were isolated from the fermentation broth of B. thailandensis MSMB43 (Fig. 6) . Thailanstatins belong to the FR901464-family of microbial products that have a heavily decorated pyran ring at one end and an acetyl group or a dimethyl acetyl group at the other end. They differ from FR901464 by lacking an unstable hydroxyl group and by having an extra carboxyl moiety. Those differences endow thailanstatins with a significantly greater stability than FR901464 under physiologically relevant conditions [30] .
This gene cluster contains 15 ORFs, which include tstC-DEFGHI coding for a nine-module hybrid PKS-NRPS pathway, tstBJO for three discrete AT enzymes, tstA for a LuxRtype pathway regulator, and genes for tailoring enzymes, self-resistance and other functionally unknown proteins. A model for the biosynthesis of thailanstatins was proposed [30] .
In vitro assays showed that thailanstatins inhibit premRNA splicing as potently as FR901464, with IC 50 values in the single to sub μM range. Cell-based assays indicated that thailanstatins also possess potent antiproliferative activities in representative human cancer cell lines, with GI 50 values in the single nM range [30] . Thailanstatins also showed promising application as potential glaucoma therapeutic agents due to their modulation activity against the glucocorticoid receptor splicing process [24] .
Conclusions and perspective
Development of new and powerful bacterial molecular genetic tools in conjunction with vast bacterial genome data in the public domain has evidently catapulted the discovery of an amazing array of natural products from Burkholderia sp. (Figs. 1, 2, 3, 4, 5, 6 ). The structural diversity and functional diversity of those compounds firmly support Burkholderia sp. as a new source of bioactive natural products. Among those Burkholderia strains explored, B. thailandensis E264 is unequivocally the champion from which 21 putative biosynthetic gene clusters were predicted with the antiSMASH program [5, 33] ( Table 2 ) and many interesting natural products have been discovered, including betulinan/terferol analogues [3] , capistruin [25] , malleilactone/burkholderic acid [4, 17] , thailandamides and thailandamide lactone [22, 23, 41] , and thailandepsins/burkholdacs [2, 58, 59] (Fig. 7) . Furthermore, all discussed examples of genome-guided natural product discovery covered in this mini-review have occurred within the last 5 years (2008-present). It is thus almost a certainty that many more interesting natural products will be discovered from Burkholderia sp. with or without genome-guided approaches.
Genome-guided natural product discovery is a smart way of discovery. It is particularly suitable for small Table 2 Putative natural product biosynthetic gene clusters predicted in the genome of B. thailandensis E264 and compounds actually identified a Bactobolins were discovered with a conventional natural product approach [7, 50] laboratories with very limited manpower and resources, because it does not require a large and sophisticated production and screening facility and resources that are otherwise necessary for the conventional high-throughput natural product discovery programs. Nevertheless, there are challenges for genome-guided natural product discovery in Burkholderia sp. and in microorganisms in general. Firstly, for those using characterized natural product biosynthetic gene cluster sequences as templates to search and identify cryptic gene clusters, there is a good chance to discover natural products that have a similar molecular scaffold as the existing compounds, as seen in the cases of capistruin [25] , thailandepsins [58, 59] , and thailanstatins [30] . Secondly, the inherent instability and often extremely low yield of many microbial natural products, such as the malleilactone/burkholderic acid [4, 17] , the thailandamides [22, 23, 41] and thailanstatins [30] , always remains a technical barrier and hampers the pace of discovery. Thirdly, the irregularity of deduced biosynthetic pathways, such as in the case of malleilactone/burkholderic acid [4, 17] , often prevents a reliable structural prediction. Lastly, for bacteria species classified as category B (or A) agents, such as B. mallei and B. pseudomallei, access to their metabolic potential is often restricted due to a lack of BSL-3 facility by most natural product researchers. Overall, those examples of successful natural product discovery from Burkholderia sp. can provide a very useful guidance for future exploration of other Gram-negative bacteria as a new source of natural products. Future efforts should focus on isolating and sequencing more microbial species from diverse environments, on developing more effective and versatile bacterial genetic tools for a wide range of microbial isolates, and on adopting more bioactivity assay methods to reveal the best possible uses of newly discovered natural products. 
